Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111540 · ClinicalTrials.gov registry record · Phase 3
Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT00111540: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00111540 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 456 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111540, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.
Primary Outcome
Change in HbA1c from Visit 1 to each visit up to open-ended study termination
Interventions
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2002-11 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00111540 record still lists
NCT00111540 is an interventional study that assigns participants to a tested intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 1 intervention - of which exenatide is the first listed.
NCT00111540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111540 about?
NCT00111540 is a clinical study titled "Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes". This open label study is designed to assess long term glucose control, as measured by hemoglobin A1c (HbA1c) and to evaluate long term safety and tolerability in subjects with type 2 diabetes mellitus who receive subcutaneously injected exenatide administered twice a day.
What is the current status of trial NCT00111540?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2002-11. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00111540?
The interventions under investigation include: exenatide (DRUG).
Who is sponsoring clinical trial NCT00111540?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00111540's enrollment target sits among peer trials
456 827th of 2000 higher than 1,172 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04462302 · 456 participants · NA
An Internet-based Program to Help Cancer Survivors Manage Pain
- NCT05820919 · 456 participants · NA
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
- NCT06254612 · 456 participants · Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
- NCT06457841 · 456 participants · NA
Stress and Resilience
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia